The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. - Wikidata - wikimedia - TriplyDB

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.

http://www.wikidata.org/entity/Q34038031

about

The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics PI3K and AKT: Unfaithful Partners in Cancer Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.Sustained proliferation in cancer: Mechanisms and novel therapeutic targets Genotype directed therapy in murine mismatch repair deficient tumors Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.Genetically engineered mouse models of PI3K signaling in breast cancer.NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation.Cell specific apoptosis by RLX is mediated by NFκB in human colon carcinoma HCT-116 cells.AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells.Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.mTOR pathway in colorectal cancer: an update.Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance.Targeting mTOR network in colorectal cancer therapy PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer.The promise of mTOR inhibitors in the treatment of colorectal cancer.Targeting PI3K in Cancer: Any Good News?Targeting the mTOR signaling network for Alzheimer's disease therapy.Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit.Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress.Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.PTRF suppresses the progression of colorectal cancers.Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.

P2860

Q26744721-0491873B-DCC4-4B1A-B0B9-0D447B5606C6 Q26766292-296A455F-3F4E-4291-A411-A7A1EA5170EA Q26781367-49576C69-8B86-47AA-92FD-809BBA48E9AE Q27852136-013AF8E8-F45B-4FE0-853D-9B0DFC5B1BAC Q28396388-C12AFDD4-A241-46DB-98B7-273DEB726A95 Q28534803-EDE4FC33-DFEB-4CC0-A347-1D6A52A92CAB Q33776641-20E253A4-03CF-4413-B765-FC85B70CCCD3 Q33934922-CE9EDA60-BF3D-48DE-9F79-51E554EA99FB Q33999493-174B0B87-4EF1-49E9-A1A3-EDF330911D1B Q34182679-F73D543A-5416-4B40-8394-481D162D56D9 Q34188530-2B72B0D1-BFFB-467D-B86A-75274DEB7683 Q34332175-9A3933BA-B52F-4BF9-93B9-C0DA0C307D56 Q34679652-4DC375C3-D822-4F9B-95DC-2ABB93E5B2D6 Q35063769-99346B13-4526-428C-9926-E3C0D20AB94D Q35321647-F7EA9745-67AB-4E90-B5F8-A2FD6192042C Q35987253-070024C7-A92C-4292-8035-E711C945284E Q35987363-65FA7BBB-21AE-482F-BFE6-991B694019CB Q36471425-E8A1FE70-AB72-4D20-91C7-FDF9EEA2332F Q36985432-A25C01DB-E186-4D8B-883E-367B36E12694 Q37632641-5359F01F-8CD4-4C77-ABCC-CDAF2D0B3EA7 Q37649634-55894398-9B7A-43B6-9608-84B658C4A722 Q37660260-5133B345-1C36-4072-9832-CEA5F7A5CD7F Q37687348-FABB4583-B137-4986-8B27-81B5066B634B Q37708005-437DE171-A82C-453F-BA37-5A541D5E82DB Q37727180-2B608059-6088-4BCE-B593-FB62D50FABF2 Q38042938-3201BC6A-4126-42EA-AA80-DBF2F954888A Q38043507-F4F0299B-D018-4C52-ADB8-989B17426260 Q38105322-D77C3EEB-B28D-4588-B753-1207F66A5168 Q38121524-CA470BF1-C8F0-4939-8A40-F47E75E62D15 Q38208069-EB65E117-2708-4325-8C97-A95C88E61FFB Q38375141-7F7ABB4D-1AB6-424F-B6C9-418E4098EB4F Q38705367-10EE2033-A8AA-490A-8EA7-6BBF85503290 Q38824026-0B292628-9FB0-40F3-8E66-C9EFBEBCD553 Q38946538-0B9A86B9-D18A-45A0-A110-8931787D2837 Q39067602-2A5B83AB-0E9F-4F6A-8ABF-A3A843893547 Q39255433-ED085140-C46A-40E0-8169-315C0713FC24 Q39735209-89D77F55-01B2-440C-8DCB-C2588459E62C Q40509393-1673BABB-3D0E-4570-96F3-8CBE4B7B8910 Q41472038-DDFBE537-3C75-47E1-9B75-EC088A837E29 Q42085487-9E2E277E-393C-474E-91F2-2B2B295E78E5

P2860

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.

http://www.wikidata.org/entity/Q34038031

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@ast

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@en

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@nl

type

label

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@ast

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@en

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@nl

prefLabel

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@ast

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@en

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@nl

P1433

Q34038031-E706C25F-D9DC-408B-9BD4-C269005D1A8D

P1476

Q34038031-159CF392-1EE8-4A82-A5F0-D90E05DB51FC

P2093

Q34038031-03481D27-5F45-4D1D-896E-0366F3F34787

Q34038031-09134F3A-C5B9-427F-AC2D-370EAA576B67

Q34038031-142B3CB7-3395-4EE9-BCCC-21FF25E7982A

Q34038031-2CA69441-7AE0-4AFD-8B80-F986EE0043B7

Q34038031-2E054B8F-D514-4053-81AD-20D4C2F73E3A

Q34038031-319831BD-9864-4545-8099-5952E02272F5

Q34038031-8028539B-29D7-493E-825C-6BE3075AF2B9

Q34038031-87634B01-BFA4-4039-89C8-E0133FF033B9

Q34038031-A35A3AE8-A7CE-418B-80F9-1981BA809A75

Q34038031-BF127FA7-D885-4BA5-9E2F-1596379A23F2

P2860

Q34038031-040BE6FB-95CF-46E8-B4F5-20E6F465541B

Q34038031-04D824A3-75B0-40B5-9196-1FF76E98B422

Q34038031-0CCDBB87-F702-4B17-916B-B2061702EA8C

Q34038031-12AB6913-4F32-4AC1-A018-1123CE8BEAE6

Q34038031-13BE99E2-B2C4-4FB5-BB70-24945C699FBF

Q34038031-14B2E375-6CAC-41FB-97EA-5A6BED1D1870

Q34038031-16921DF8-74A1-4272-B135-003610A68858

Q34038031-1A218286-7880-4CB8-B5E4-28FB5749C546

Q34038031-1B1F843E-6323-489B-B1F7-41FF2A02A787

Q34038031-1F2A3F38-EFC0-42A2-A193-C6802FA32A19

P304

Q34038031-B298FFDA-D3BE-4B8F-B1CB-3D9E7EB78EB5

P31

Q34038031-CDC9A254-866F-49DC-BF62-CF6C5FB45B1A

P356

Q34038031-0BE8C3B6-1474-49A4-B209-A64A31FA9B2C

P407

Q34038031-25C85630-3D6E-48BA-AD95-F1EF1F8F08DD

P433

Q34038031-B9870AC2-105E-4ADD-BDF1-9C4A9B88FF5D

P478

Q34038031-259AAAB1-0D30-4972-9FF9-01D855078607

P50

Q34038031-7CB64D37-DB82-4C63-82B1-9B70D5C8F7EF

P577

Q34038031-A5A17A4C-9B39-4166-8BC3-FEDFC5F85F92

P5875

Q34038031-6970BB12-FACD-42D5-AA85-F04619D26FF4

P698

Q34038031-3B40D7E3-841E-4EA4-BDDE-CBB864D8CF9E

P921

Q34038031-A79E88C2-C2CB-459B-BF53-60F83D646872

P932

Q34038031-C3E6B041-2195-4D85-AA51-94DB66B36879

P356

JOURNAL.PONE.0025132

P1433

P1476

The dual PI3K/mTOR inhibitor N ...... A wild-type colorectal cancer.

@en

P2093

Eric S Martin

http://www.w3.org/2001/XMLSchema#string

Erin M Coffee

http://www.w3.org/2001/XMLSchema#string

Kenneth E Hung

http://www.w3.org/2001/XMLSchema#string

Larissa Georgeon Richard

http://www.w3.org/2001/XMLSchema#string

Lydia Lee

http://www.w3.org/2001/XMLSchema#string

Mark J Sinnamon

http://www.w3.org/2001/XMLSchema#string

Michael P Richardson

http://www.w3.org/2001/XMLSchema#string

Peng-Chieh Chen

http://www.w3.org/2001/XMLSchema#string

Roderick T Bronson

http://www.w3.org/2001/XMLSchema#string

Wei Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

mTOR: from growth signal integration to cancer, diabetes and ageing

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.

Cancer statistics, 2010

High frequency of mutations of the PIK3CA gene in human cancers

P304

e25132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0025132

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51687556

http://www.w3.org/2001/XMLSchema#string

P698

21966435

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3180374

http://www.w3.org/2001/XMLSchema#string